Rafael Guerrero-Preston
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$8.3MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $8.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 7, 2026 | NIH | SBIR Phase II Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings | $900K | LIFEGENE-BIOMARKS, INC. |
| May 13, 2026 | NIH | STTR Phase II Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | $366K | LIFEGENE-BIOMARKS, INC. |
| May 14, 2025 | NIH | SBIR Phase II Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings | $913K | LIFEGENE-BIOMARKS, INC. |
| Nov 28, 2024 | NIH | STTR Phase II Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | $1.5M | LIFEGENE-BIOMARKS, INC. |
| Apr 22, 2024 | NIH | STTR Phase II Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | $276K | LIFEGENE-BIOMARKS, INC. |
| Sep 20, 2023 | NIH | SBIR Phase II Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings | $292K | LIFEGENE-BIOMARKS, INC. |
| May 2, 2023 | NIH | SBIR Phase II Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | $1.0M | LIFEGENE-BIOMARKS, INC. |
| Jul 15, 2022 | NIH | SBIR Phase II Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | $1.0M | LIFEGENE-BIOMARKS, INC. |
| Sep 20, 2021 | NIH | SBIR Phase II Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | $400K | LIFEGENE-BIOMARKS, INC. |
| Apr 30, 2021 | NIH | SBIR Phase II Precision methylation biomarkers linked to cancer disparities | $734K | LIFEGENE-BIOMARKS, INC. |
| Jun 23, 2020 | NIH | SBIR Phase II Precision methylation biomarkers linked to cancer disparities | $803K | LIFEGENE-BIOMARKS, INC. |
| Sep 24, 2019 | NIH | SBIR Phase II Precision methylation biomarkers linked to cancer disparities | $206K | LIFEGENE-BIOMARKS, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#110
Awards as PI#97
Patents#505
Companies
- LIFEGENE-BIOMARKS, INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.